The total return over the past 12 months is +72.17% vs. +16.94% for the S&P 500. So far it's up -6.09% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +72.17% | +34.62% | +0.75% | +23.56% | +20.30% | +1.38% |
| Total Return CAGR | +72.17% | +34.62% | +0.75% | +23.56% | +20.30% | +1.38% |
| Revenue CAGR | +16.85% | +37.73% | +44.14% | +128.75% | +62.11% | +40.30% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (370.34%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Arrowhead Pharmaceuticals, Inc. (ARWR)
| Year | Start price | End price | ARWR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $66.39 | $62.35 | (6.09%) | +14.51% | (20.60%) |
| 2025 | $18.80 | $66.39 | +253.14% | +17.72% | +235.42% |
| 2024 | $30.60 | $18.80 | (38.56%) | +24.89% | (63.45%) |
| 2023 | $40.56 | $30.60 | (24.56%) | +26.19% | (50.75%) |
| 2022 | $66.30 | $40.56 | (38.82%) | (18.17%) | (20.65%) |
| 2021 | $76.73 | $66.30 | (13.59%) | +28.74% | (42.33%) |
| 2020 | $63.43 | $76.73 | +20.97% | +18.37% | +2.60% |
| 2019 | $12.42 | $63.43 | +410.71% | +31.22% | +379.49% |
| 2018 | $3.68 | $12.42 | +237.50% | (4.56%) | +242.06% |
| 2017 | $1.55 | $3.68 | +137.42% | +21.70% | +115.72% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
